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Plant stanol ester is a natural compound which is used as a cholesterol-lowering ingredient in functional foods and food
supplements. The safety and efficacy of plant stanol ester have been confirmed in more than 70 published clinical studies and
the ingredient is a well-established and widely recommended dietary measure to reduce serum cholesterol. Daily intake of 2 g plant
stanols as plant stanol ester lowers LDL-cholesterol by 10%, on average. In Europe, foods with added plant stanol ester have been
on the market for 20 years, and today such products are also available in many Asian and American countries. Despite the well-
documented efficacy, the full potential in cholesterol reduction may not be reached if plant stanol ester is not used according to
recommendations. This review therefore concentrates on the optimal use of plant stanol ester as part of dietary management of
hypercholesterolemia. For optimal cholesterol lowering aiming at a lower risk of cardiovascular disease, plant stanol ester should
be used daily, in sufficient amounts, with a meal and in combination with other recommended dietary changes.
1. Introduction
Atherosclerotic vascular diseases are themost common cause
of mortality worldwide. High cholesterol induces a third of
all cardiovascular disease, causing about 17 million deaths
per year [1]. Lowering LDL-cholesterol is a central target in
the prevention of cardiovascular diseases, especially coronary
heart disease. It is estimated that for every 1% reduction in
LDL-cholesterol concentration, there is a corresponding 1 to
2%decrease in the risk of coronary heart disease [2, 3]. Recent
research findings further emphasize the importance of LDL-
cholesterol management in the prevention of cardiovascular
diseases [4, 5].
Atherosclerosis develops during a long period of time
so the earlier the lipid management is initiated the more
likely the atherosclerotic vascular diseases can be prevented
[6]. Since atherosclerosis is largely a result of an unhealthy
lifestyle, lifestyle intervention should be favored in its pre-
vention and management. Central international prevention
and treatment guidelines therefore stress the importance of
diet and lifestyle as the cornerstones of hypercholesterolemia
management [7–9]. A big advantage of this approach is that
lipid management can be safely implemented from early
age.
Permanent changes in lifestyle may be hard to achieve,
however, and people with elevated cholesterol levels may
not always be motivated enough to make the recommended
changes [10]. One solution is to use cholesterol-lowering
functional foods and food supplements which offer an easy
and convenient way of lowering cholesterol through diet.
Plant stanol ester is one of the most established choles-
terol-lowering functional food ingredients in the world. Its
efficacy has been verified in more than 70 published clinical
studies, and its use as part of a cholesterol-lowering diet is
recommended by a number of international nongovernmen-
tal and scientific organisations [7–9]. However, permanent
reductions in serum cholesterol can be achieved only through
sufficient daily use of plant stanol ester as part of daily meals.
This review thus concentrates on highlighting the correct use
of plant stanol ester as part of a healthy lifestyle.
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2. What Is Plant Stanol Ester?
Plant stanols and plant sterols are natural compounds which
are present in our daily diet. Their main dietary sources are
vegetables, fruit, vegetable oils, cereals, and nuts [11]. A west-
ern diet typically contains 20 to 30mg/d plant stanols and
around 300mg/d plant sterols [12, 13]. However, this intake
from naturally occurring sources is too low to bring about
a significant cholesterol-lowering effect, which is why plant
stanols and plant sterols are added to foods and food supple-
ments.
Plant stanols are added to commercially available choles-
terol-lowering products as plant stanol ester. This fat-soluble
compound is formed of plant stanols and vegetable oil based
fatty acids through esterification. Adding plant stanols as
plant stanol ester ensures the cholesterol-lowering efficacy of
the ingredient without altering the taste or the texture of the
food product.
2.1. Mode of Action. Plant stanol ester works by partly
inhibiting the absorption of cholesterol in the small intestine.
Plant stanol ester is first hydrolysed to plant stanols and fatty
acids. After this, plant stanols interfere with the solubilisation
of cholesterol, that is, the incorporation of cholesterol into
mixed micelles [14]. This is possible because of the slight
structural dissimilarities of plant stanols and cholesterol.
Other mechanisms, such as activation of certain transport
proteins in the enterocytes, may also be involved in the
process. Plant stanols themselves are virtually not absorbed
but are rapidly excreted from the body in feces [15].
Consumption of plant stanol ester inhibits the absorption
of both dietary cholesterol, that is, the cholesterol coming to
the digestive tract in food, and biliary cholesterol, that is, the
cholesterol coming to the digestive tract in bile. With 2 g/d
plant stanols, cholesterol absorption efficiency is reduced by
about 50% [16, 17]. Optimal cholesterol absorption inhibition
requires that plant stanol ester is consumed with a meal
because bile is excreted into the digestive tract following a
meal.The reduced cholesterol absorption achieved with plant
stanol ester leads to significantly reduced levels of serum total
and LDL-cholesterol [16, 18–21].
2.2. Efficacy in LDL-Cholesterol Lowering. Plant stanol ester
is one of the most established functional food ingredients in
the world. Research evidence consistently shows that a daily
intake of 2 g of plant stanols (as plant stanol ester) reduces
total and LDL-cholesterol concentration by 10%, on average
[22, 23], with no effect on HDL-cholesterol concentration
[24–26].
The average 10% reduction in LDL-cholesterol concen-
tration can be detected after only 1 to 2 weeks’ daily con-
sumption of plant stanol ester (2 g/d plant stanols) [27–31].
More important, however, is that the reduction in blood
LDL-cholesterol is persistent as long as plant stanol ester is
included in the daily diet (Figure 1). The study by Miettinen
et al. (1995) [24] was the first long-term study showing that
1.8–2.6 g/d plant stanols as part of a daily diet effectively
reduced LDL-cholesterol concentration by 12–14% in amildly
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Figure 1: The full LDL-cholesterol-lowering effect of plant stanol
ester can be detected after the daily consumption of 2 g/d plant
stanols for 2 weeks. The effect is sustained as long as plant stanol
ester is included in the daily diet; the longest intervention period in
a clinical study has been 85 weeks. If the consumption is stopped,
the plant stanol ester specific cholesterol-lowering effect will be lost
within 1-2 weeks (modified from [18, 22, 24, 27, 32, 33, 35–37]).
hypercholesterolemic population. The intervention period
in this study lasted for 12 months. The long-term effect of
plant stanol ester has been confirmed in other studies, in
which the intervention period has lasted from 12 months
to 85 weeks [32, 33]. It is noteworthy that when the daily
consumption of plant stanol ester is stopped, serum LDL-
cholesterol concentration rapidly increases towards initial
levels [24].
2.3. Safety. Studies on plant stanol ester have been con-
ducted in several population groups, including normoc-
holesterolemic ormildly ormoderately hypercholesterolemic
adults and children, individuals with familial hypercholes-
terolemia, individuals with type 1 or type 2 diabetes, and
patients with coronary heart disease. These studies have
included subjects from Europe, Americas, and Asia [38]. No
adverse effects have been reported in connection with the use
of plant stanol ester in the above-mentioned clinical studies
or in regular consumption of plant stanol ester containing
products.
Plant stanols are stable molecules that are not altered in
food manufacturing or preparation processes. Being micro-
biologically inert they are not effected by fermentation [39]
nor are they oxidized when heated [40]. Likewise they are not
metabolized in the body but excreted intact [15].
The United States Food and Drug Administration (U.S.
FDA) has acknowledged the GRAS status (Generally Recog-
nised as Safe status) of plant stanol ester [41], and the
safety of plant stanol ester has been evaluated by local food
safety authorities before entering the respective markets.
Furthermore, the Joint FAO/WHO Expert Committee on
Food Additives (JECFA) has considered plant stanol ester as
safe [39].
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3. Optimal Use of Plant Stanol Ester
The key to successful serum cholesterol reduction with
plant stanol ester is the correct use of this ingredient. Since
hypercholesterolemic patients typically discuss their diet with
healthcare professionals, the latter need to be informed on the
optimal use of plant stanol ester. Key considerations that need
to be taken into account when plant stanol ester is used to
manage hypercholesterolemia are discussed below.
3.1. Sufficient and Daily Consumption. Most of the clinical
studies assessing the cholesterol-lowering effect of plant
stanol ester have been conducted with a 2 g/d intake [23] and
research evidence consistently shows that a daily intake of 2 g
plant stanols lowers serum LDL-cholesterol concentration by
10%, on average [22]. International guidelines also encourage
clinicians to consider this daily intake of plant stanols (2 g/d)
as part of an overall healthy diet [7–9]. This recommended
intake is also communicated to consumers in food labeling.
Some recent research indicates that further cholesterol
reduction can be obtained with higher doses than those
currently recommended, and also the safety of plant stanol
ester has been confirmed with daily intakes of plant stanols
up to 9 g [23, 42, 43].
Despite clear consumer communication, the average
intake of plant stanols from enriched products is typically
well below the recommended 2 g/d. The same concerns plant
sterols. For example, a Finnish study showed that more than
half of the users of foods with added plant stanol or plant
sterol ester did not reach the recommended daily intake
[44]. Another example is a survey on consumer purchase
behaviour which included 91,000 households in the Nether-
lands, Belgium, United Kingdom, France, and Germany [45].
According to this survey, the average intake of plant stanols
or sterols was only 0.35–0.86 g/day.
A too low daily intake of plant stanols or plant sterols
is problematic since the expected cholesterol-lowering effect
may not be reached. Based on a series of meta-analyses which
were published in a rebuttal by Musa-Veloso and Poon [46]
it can be calculated that daily intakes of 1.0, 1.5, and 2.0
grams of plant stanols will bring about average reductions of
5.3%, 7.4%, and 9.1%, respectively, in serum LDL-cholesterol
concentration. Thus, the effect of daily intake of 1.0 grams
or less may easily be hidden behind the natural variation in
serum cholesterol concentration. Furthermore, the European
Food Safety Authority, EFSA, has concluded that 1.5–2.4 g/d
plant stanols or plant sterols are needed in order to reach a
significant 7–10% reduction in serum LDL-cholesterol [47].
The low plant stanol intake may be due to irregular use of
foodswith added plant stanol ester or too small daily portions
of such foods. Therefore, it is important that healthcare
professionals emphasize the sufficient daily consumption of
plant stanol ester when they discuss diet with their patients.
3.2. Best Efficacy When Consumed with a Meal. For opti-
mum efficacy, it is important to consume foods and food
supplements with added plant stanol ester with daily meals
[25, 48, 49]. This is due to the mechanism of action of plant
Table 1: Key dietary interventions to reduce serum total and LDL-
cholesterol levels (modified from [7, 34]).
Dietary intervention Average reductionin LDL-cholesterol
Replacement of saturated and trans fat with
unsaturated fats 5–10%
Increase in dietary fibre intake 5%
Utilization of functional foods with added
plant stanols 10–15%
Cumulative estimate 20–30%
stanol ester, where plant stanols partly replace cholesterol
in mixed micelles which are formed in the digestive tract.
Micelle formation requires sufficient amounts of fat and other
macronutrients, and without a meal the daily plant stanol
ester dose may bring only around 50% of optimal efficacy
[50].
Also the esterification of plant stanols to plant stanol
ester is per se an efficient way of ensuring that plant stanols
are effectively incorporated into mixed micelles for effective
reduction of cholesterol absorption [51]. Consumption with
a meal, however, ensures that bile is excreted to the digestive
tract and that the reabsorption of biliary cholesterol can be
inhibited with plant stanol ester.
Most studies have assessed the effects of taking 2 grams
of plant stanols in two or more portions per day. However,
taking the daily dose of plant stanols in one dose with a
main meal has been shown to be as effective in lowering
serum LDL-cholesterol concentrations as splitting the dose
over three meals [48].
3.3. Additive Effect to Other Cholesterol-Lowering Dietary
Measures. Plant stanol ester effectively reduces serum total
and LDL-cholesterol concentration as part of any diet. It
works in a typical western diet with a relatively high content
of saturated fat and cholesterol [24] as well as diets low
in saturated fat and cholesterol [26, 37, 52, 53]. Thus, the
average 10% reduction in LDL-cholesterol is independent of
the background diet.
Since the effect of plant stanol ester is additive to other
cholesterol-lowering dietary changes [37, 52], it should opti-
mally be consumed as part of an overall heart-healthy diet.
A recommended diet including plant stanol ester can reduce
LDL-cholesterol by up to 20–30% (Table 1) [7, 34, 37].
3.4. Additive Effect to Statins. International guidelines rec-
ommend the use of plant stanol ester also in combination
with cholesterol-lowering statin medication [7–9].These two
cholesterol-lowering means have different mechanisms of
action, and consequently the cholesterol-lowering effect of
plant stanol ester adds to the effect of statins. This additive
effect has been shown in several randomized, controlled
clinical trials where patients on stable statin medication
have included foods with added plant stanol ester in their
diet, resulting in an incremental LDL-cholesterol reduction
4 Cholesterol
of 10%, on average [17, 33, 35, 54–58]. This 10% reduction
achieved with plant stanol ester is larger than that of doubling
the statin dose [59].
4. For Which Patients Should Plant Stanol
Ester Be Considered?
Recently, a Consensus Panel of the European Atherosclerosis
Society published a Consensus Statement on the role of plant
stanols and plant sterols in the management of dyslipidemia
andprevention of cardiovascular disease [14].ThisConsensus
Statement as well as many other international guidelines
[7–9, 60–64] encourages clinicians to consider the use of
functional foods with added plant stanols (2 g/d) as an aid
to other beneficial lifestyle changes, also in conjunction
with cholesterol-lowering medication. Key patient groups for
which the daily use of plant stanol ester can be considered
are listed as an adjunct to a general healthy diet and lifestyle
[7–9, 14, 61–64] as follows:
(1) individuals who have elevated serum cholesterol lev-
els and are at low or intermediate global cardiovas-
cular risk but who do not need cholesterol-lowering
medication,
(2) high and very high risk patients, such as patients with
diabetes, who fail to achieve LDL-cholesterol targets
on statins alone or are statin intolerant,
(3) adults and children (from the age of 6 years) with
familial hypercholesterolemia.
5. Conclusions
Atherosclerotic cardiovascular events are still the number
one killer in the world. However, if LDL-cholesterol level
was kept low throughout life or if high LDL-cholesterol
was effectively lowered, the development of atherosclerosis
could be prevented or the progress of atherosclerotic plaque
formation reversed. Diet plays a central role in the life-
long management of blood cholesterol levels, and because
recommended dietary changes are an inexpensive, safe, and
effective way to reduce cholesterol, all dietary measures,
including the use of functional foods with added plant stanol
ester, should be fully utilized. However, the challenge is
that patients may find it hard to motivate themselves to
make permanent changes to their diet and lifestyle. Plant
stanol ester is a well-documented and safe dietary way to
reduce cholesterol. When used daily in sufficient amounts
and as part of the daily meals, it can reduce serum LDL-
cholesterol by on average 10%. In combination with other
recommended dietary changes, the total reduction in serum
LDL-cholesterol can be as much as 20–30%. Healthcare
professionals should actively communicate the efficacy of
a recommended cholesterol-lowering diet to their hyperc-
holesterolemic patients to increase the patients’ motivation
for dietary changes.
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